12/17/2015 · AstraZeneca completes acquisition of ZS Pharma. PUBLISHED 17 December 2015. 17 December 2015. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.
11/6/2015 · AstraZeneca said today it will acquire ZS Pharma for approximately $2.7 billion, in a deal designed to expand the buyer’s cardiovascular and metabolic disease portfolio. That portfolio will, if …
AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders.
AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. The move gives the drugs giant access to the potassium-binding compound ZS-9 (sodium zirconium cyclosilicate), a potential best-in-class treatment for hyperkalaemia, a condition linked with increased mortality in patients with chronic kidney disease, diabetes and chronic heart failure.
AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) …
AstraZeneca completes acquisition of ZS Pharma, AstraZeneca completes acquisition of ZS Pharma, AstraZeneca completes acquisition of ZS Pharma, 11/1/2015 · The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer.
11/6/2015 · Astrazeneca, UK’s second-largest drugmaker, agreed to buy ZS Pharma for $2.7 billion in cash, sweeping it from Swiss rival Actelion.
AstraZeneca completes acquisition of ZS Pharma : United Kingdom Friday, December 18, 2015, 15:00 Hrs [IST] AstraZeneca announced that the company successfully completed the tender offer for all of the outstanding shares of ZS Pharma and the subsequent acquisition of ZS Pharma as previously announced in November.
11/7/2015 · The deal would be the latest acquisition by a pharmaceutical company in what has been a record year for mergers, driven in part by transactions in the health care sector. … ZS Pharma.
Mid-Day Market Update: ZS Pharma Jumps On Acquisition News; Men’s Wearhouse Shares Slide. Contributor. Benzinga Benzinga Published. Nov 6, 2015 12:26PM EST. …
